Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Anavex Life Sciences Ord Shs (NQ: AVXL)
4.710 USD  -0.070 (-1.46%)
Official Closing Price  /  Updated: 5:19 PM EDT, Jul 10, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 535,300
Open 4.880
Bid (Size) 4.650 (10)
Ask (Size) 4.820 (3)
Prev. Close 4.780
Today's Range 4.680 - 4.880
52wk Range 2.200 - 6.310
Shares Outstanding 44,660,062
Dividend Yield N/A
Performance
YTD
+64.11%
+64.11%
1 Month
+16.01%
+16.01%
3 Month
+53.92%
+53.92%
6 Month
+57.53%
+57.53%
1 Year
+46.73%
+46.73%
Top News
More News
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)
from GlobeNewswire News Releases
Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett Syndrome
from GlobeNewswire News Releases
More News
Read More
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
from GlobeNewswire News Releases
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease
from GlobeNewswire News Releases
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)
from GlobeNewswire News Releases
Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates
from GlobeNewswire News Releases
Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020
from GlobeNewswire News Releases
Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease
from GlobeNewswire News Releases
Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19
from GlobeNewswire News Releases
Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders
from GlobeNewswire News Releases
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS)
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.